Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA (2016 - 2025)

Historic EBITDA for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$40.0 million.

  • Vanda Pharmaceuticals' EBITDA fell 29981.03% to -$40.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$150.1 million, marking a year-over-year decrease of 27742.71%. This contributed to the annual value of -$150.1 million for FY2025, which is 27742.71% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its EBITDA stood at -$40.0 million for Q4 2025, which was down 29981.03% from -$31.0 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBITDA ranged from a high of $12.7 million in Q2 2021 and a low of -$40.8 million during Q1 2025
  • Moreover, its 5-year median value for EBITDA was -$6.3 million (2023), whereas its average is -$7.6 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' EBITDA skyrocketed by 462831.86% in 2021, and later plummeted by 49342.05% in 2024.
  • Vanda Pharmaceuticals' EBITDA (Quarter) stood at $9.0 million in 2021, then dropped by 23.27% to $6.9 million in 2022, then crashed by 199.65% to -$6.9 million in 2023, then crashed by 45.41% to -$10.0 million in 2024, then tumbled by 299.81% to -$40.0 million in 2025.
  • Its EBITDA was -$40.0 million in Q4 2025, compared to -$31.0 million in Q3 2025 and -$38.2 million in Q2 2025.